Piramal Pharma Secures Improved NSE ESG Rating of 65 for FY26
Piramal Pharma Ltd 路 Others (Uncategorized) 路 03 Sept 2026, 7:58 pm
Piramal Pharma Secures Improved NSE ESG Rating of 65 for FY26 On 3rd Sep'26, Piramal Pharma disclosed an upgraded ESG rating of 65 for FY26, assigned voluntarily by NSE Sustainability Ratings and Analytics. This reflects a marginal improvement from the previous score of 64. The rating was independently prepared using public domain data without formal engagement by the company. The slight upward revision highlights Piramal Pharma's incremental progress in sustainable and responsible corporate operations.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund 路 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 路 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. 路 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. 路 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 路 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 路 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 28 Oct 2026
- Please find enclosed unaudited financial results for Q2 FY 27 路 28 Oct 2026
